share_log

Teladoc Health | 8-K: Teladoc Health Reports Third Quarter 2024 Results

Teladoc Health | 8-K: Teladoc Health Reports Third Quarter 2024 Results

Teladoc Health | 8-K:Teladoc Health 公佈2024年第三季度業績
美股SEC公告 ·  10/31 04:16

牛牛AI助理已提取核心訊息

Teladoc Health, Inc. reported its financial results for the third quarter of 2024 on October 30, 2024. The company experienced a 3% decrease in revenue year-over-year, totaling $640.5 million, and a net loss of $33.3 million, or $0.19 per share. Adjusted EBITDA also saw a decline of 6% to $83.3 million. Despite the downturn, the Integrated Care segment saw a revenue increase of 2% to $383.7 million and an improved adjusted EBITDA margin of 17.7%. Conversely, the BetterHelp segment's revenue fell by 10% to $256.8 million, with an adjusted EBITDA margin of 5.9%. CEO Chuck Divita expressed commitment to execution and potential for growth, indicating that 2025 will be a pivotal year for repositioning. The company's U.S. revenue decreased by 6%, while International revenue grew by 15%. A significant non-cash goodwill impairment...Show More
Teladoc Health, Inc. reported its financial results for the third quarter of 2024 on October 30, 2024. The company experienced a 3% decrease in revenue year-over-year, totaling $640.5 million, and a net loss of $33.3 million, or $0.19 per share. Adjusted EBITDA also saw a decline of 6% to $83.3 million. Despite the downturn, the Integrated Care segment saw a revenue increase of 2% to $383.7 million and an improved adjusted EBITDA margin of 17.7%. Conversely, the BetterHelp segment's revenue fell by 10% to $256.8 million, with an adjusted EBITDA margin of 5.9%. CEO Chuck Divita expressed commitment to execution and potential for growth, indicating that 2025 will be a pivotal year for repositioning. The company's U.S. revenue decreased by 6%, while International revenue grew by 15%. A significant non-cash goodwill impairment charge of $790 million was recorded, attributed to the BetterHelp segment, which did not impact the provision for income taxes. The company's cash flow from operations increased slightly in the third quarter to $110.2 million, and free cash flow improved to $79 million. Teladoc Health provided a financial outlook for the Integrated Care segment, expecting a revenue growth percentage of 0% to 2.5% for the fourth quarter and a low to mid-single-digit growth for the full year of 2024.
teladoc health公司報告了2024年第三季度的財務業績,日期爲2024年10月30日。該公司年度營業收入下降了3%,總計64050萬美元,淨虧損爲3330萬美元,每股虧損0.19美元。調整後的EBITDA也下降了6%,至8330萬美元。儘管出現下滑,綜合護理業務部門的營業收入增長了2%,達到38370萬美元,並改善了調整後的EBITDA利潤率,達到17.7%。相反,BetterHelp業務部門的營業收入下降了10%,至25680萬美元,調整後的EBITDA利潤率爲5.9%。CEO Chuck Divita表達了對執行和增長潛力的承諾,表示2025年將是重新定位的關鍵一年。該公司的美...展開全部
teladoc health公司報告了2024年第三季度的財務業績,日期爲2024年10月30日。該公司年度營業收入下降了3%,總計64050萬美元,淨虧損爲3330萬美元,每股虧損0.19美元。調整後的EBITDA也下降了6%,至8330萬美元。儘管出現下滑,綜合護理業務部門的營業收入增長了2%,達到38370萬美元,並改善了調整後的EBITDA利潤率,達到17.7%。相反,BetterHelp業務部門的營業收入下降了10%,至25680萬美元,調整後的EBITDA利潤率爲5.9%。CEO Chuck Divita表達了對執行和增長潛力的承諾,表示2025年將是重新定位的關鍵一年。該公司的美國營業收入下降了6%,而國際營業收入增長了15%。BetterHelp業務部門出現重大的非現金商譽減值費用,達到了79000萬美元,歸因於BetterHelp業務部門,這並未影響所得稅準備。該公司的運營現金流在第三季度略微增加至11020萬美元,自由現金流提高至7900萬美元。teladoc health爲綜合醫療保健業務部門提供了財務展望,預計第四季度營業收入增長百分比爲0%至2.5%,2024年整體年度預計爲低到中單位數位增長。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。